Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat
AGL Share
Trades37
AGL
Live RNS
AGL Share
Charts
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
AGL Company
Research
AGL Company
Timeline
- There is currently no data for AGL
IN BRIEF: Angle highlights supportive data for DNA analysis tool
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Latest AGL News
- Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study
5 Jun 2019 - Angle reveals positive results from latest Parsortix study
31 May 2019 - Angle's Parsortix system used in more groundbreaking research
26 Apr 2019 - Angle's Parsortix System Used In Further "Groundbreaking" Research
26 Apr 2019 - US Cancer Centre Uses Angle's Parsortix System For Assessments
18 Apr 2019 - Angle's Parsortix to be used in new Greece study
12 Apr 2019 - University Of Athens Cancer Study To Use Angle's Parsortix System
12 Apr 2019 - Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix
7 Mar 2019
Related News
IN BRIEF: Angle names Peter Collins as interim CEO
(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...
Angle touts planned name and strategy change, Groen turns executive
(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...
IN BRIEF: Angle CEO and finance lead step down after shareholder talks
Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...
Angle News
Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study
LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex plat...
Angle reveals positive results from latest Parsortix study
(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Frid...
Angle's Parsortix system used in more groundbreaking research
(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer ...
Angle's Parsortix System Used In Further "Groundbreaking" Research
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The resear...
US Cancer Centre Uses Angle's Parsortix System For Assessments
LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a ...
Angle's Parsortix to be used in new Greece study
(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomark...
University Of Athens Cancer Study To Use Angle's Parsortix System
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.T...
Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix
LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast ...
Follow the stocks
